"The only thing that does not make any sense, and perhaps you can enlighten me, is why did the share price hit a 52 week low if there are so many positive developments on the horizon?"
I think this is primarily due to the short term focus of tutes. Tute managers are compensated on a quarterly basis. So when a time horizon is inexact, they dump and wait.
Missling believes that Tutes will start buying when the Rett trial is announced, because then it becomes a math problem of time to potential payoff, but sit until then.
My experience with many biotech analysts confirms this hypothesis. Many are MBAs, not science guys, so they wait until the pivotal trial for approval is started before recommending any biotech.
Also many tutes are followers, who will wait until another big name bio tute buys first.
Market Data 
Markets 
AI
